Heron Therapeutics Inc vs Newegg Commerce Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Newegg Commerce Inc trades at $11.7 (market cap $243.30M). The key difference: Newegg Commerce Inc is far larger — about 3.6× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Newegg Commerce Inc for 14 Days on average.
| HRTX | NEGG | |
|---|---|---|
Market Cap | $68.01M | $243.30M |
Volume | 1,891,941 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $92.74 |
52-Week Low | $0.27 | $11.49 |
Typical Hold Time | 35 Days | 14 Days |
Enterprise Value | $174.75M | $213.53M |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
NEGG trades at $11.58, down 3.58% today, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 projections. Recent partnerships with Western Digital and HPE highlight strategic moves in AI and enterprise IT markets, while insider selling has created near-term pressure.
The stock presents a mixed picture with improving profitability but significant execution risks. While analyst consensus remains bullish with 100% buy ratings, the $7.75 price target suggests 33% downside from current levels. Key risks include volatile cash flows, competitive e-commerce pressures, and the need to sustain recent margin improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →